Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Bristol-Myers Squibb And Pfizer Obtain EU Approval For Eliquis

Pfizer Inc. (PFE: Quote) and Bristol-Myers Squibb Co. (BMY: Quote) announced Tuesday that the European Commission has approved Eliquis or apixaban for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation or NVAF with one or more risk factors.

The company said that Eliquis is the only oral anticoagulant that has demonstrated superior risk reduction versus warfarin in the three important outcomes of stroke and systemic embolism, major bleeding, and all-cause mortality.

Eliquis is an oral direct Factor Xa inhibitor, part of a novel therapeutic class. It is the first regulatory approval in any market for Eliquis for stroke prevention in patients with nonvalvular atrial fibrillation, the company said.

The marketing authorization for Eliquis is supported by the pivotal Phase 3 trials Aristotle and Averroes, which evaluated approximately 24,000 patients with NVAF in the largest completed clinical trial program conducted to date in this patient population.

Atrial fibrillation is the most common cardiac arrhythmia (irregular heart beat). It is estimated that approximately 6 million individuals in Europe have atrial fibrillation. The lifetime risk of developing atrial fibrillation is estimated to be approximately 25% for individuals 40 years of age or older.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an investigational oral anticoagulant discovered by Bristol-Myers Squibb.

Register
To receive FREE breaking news email alerts for Pfizer Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving mostly higher over the course of the previous week, stocks showed a notable move back to the downside during trading on Monday. With the drop on the day, the Dow pulled back well off last Friday's record closing high. After reporting four consecutive monthly increases, the National Association of Realtors released a report on Monday showing an unexpected drop in U.S. existing home sales in the month of August. NAR said existing home sales fell 1.8 percent to a seasonally adjusted annual rate of 5.05 million in August. The European Central Bank remains ready to use additional unconventional tools to counter risks to the inflation outlook and to boost the euro area economy, ECB President Mario Draghi said on Monday. "The Governing Council remains fully determined to counter risks to the medium-term outlook for inflation," Draghi said in Brussels.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.